Bavarian Nordic A/S

Bavarian Nordic A/S is a Danish biotechnology company specializing in the research, development, manufacturing, and commercialization of innovative vaccines based on viral vector technologies. Headquartered in Hellerup, Denmark, with manufacturing facilities in Denmark and Switzerland, and R&D sites in Germany plus offices across North America and Europe, it leverages proprietary platforms like MVA-BN, a non-replicating Modified Vaccinia Ankara vector designed for safety and efficacy. The company markets approved vaccines including Jynneos/Imvanex/Imvamune for smallpox and mpox, Rabipur/RabAvert for rabies, Encepur for tick-borne encephalitis, Mvabea as part of an Ebola regimen, Vivotif for typhoid, Vaxchora for cholera, and the recently approved Vimkunya for chikungunya. Bavarian Nordic plays a critical role in global public health, supplying vaccines to government stockpiles, combating outbreaks like mpox and Ebola, and expanding into travel health and biodefense, while advancing a pipeline targeting equine encephalitis and other infectious diseases.

Want to understand how we rate dividend safety? Read our full methodology